Detalhe da pesquisa
1.
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities.
Blood
; 141(5): 467-480, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322929
2.
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Blood
; 139(11): 1684-1693, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614146
3.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
4.
Mutational landscape of gray zone lymphoma.
Blood
; 137(13): 1765-1776, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961552
5.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289656
6.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184451
7.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Blood
; 127(20): 2375-90, 2016 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26980727
8.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
N Engl J Med
; 370(11): 1008-18, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450858
9.
New Agents to Treat Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(22): 2185-6, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27248633
10.
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
Blood
; 129(22): 3037-3039, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28325864
11.
CNS Bridging Radiotherapy Achieves Rapid Cytoreduction Prior to CAR T Cell Therapy for Aggressive B-Cell Lymphoma.
Blood Adv
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861344
12.
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
Blood Adv
; 8(9): 2172-2181, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38271621
13.
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
Leukemia
; 37(1): 154-163, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335261
14.
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
Haematologica
; 102(10): e404-e406, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28679653
15.
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
Blood Adv
; 5(6): 1737-1745, 2021 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749762
16.
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
Blood Adv
; 5(20): 4185-4197, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529789
17.
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Clin Lymphoma Myeloma Leuk
; 21(4): 267-278.e10, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33303421
18.
Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.
Haematologica
; 100(5): e204-6, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637052
19.
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
; 4(4): 629-637, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32074277
20.
Gene expression profiling of gray zone lymphoma.
Blood Adv
; 4(11): 2523-2535, 2020 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32516416